|Assessment Status||Rapid Review Complete|
|Indication||For the diagnosis of growth hormone deficiency (GHD) in adults.|
|Rapid review commissioned||30/08/2022|
|Rapid review completed||04/10/2022|
|Rapid review outcome||The NCPE recommends that macimorelin acetate (Ghryvelin®) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.